IDERA PHARMACEUTICALS INC's ticker is IDRA and the CUSIP is 45168K306. A total of 81 filers reported holding IDERA PHARMACEUTICALS INC in Q1 2016. The put-call ratio across all filers is 1.84 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2018 | $707,000 | +381.0% | 535,304 | +568.8% | 0.00% | – |
Q1 2018 | $147,000 | +81.5% | 80,036 | +108.4% | 0.00% | – |
Q4 2017 | $81,000 | +224.0% | 38,399 | +241.8% | 0.00% | – |
Q3 2017 | $25,000 | -74.7% | 11,233 | -80.4% | 0.00% | – |
Q2 2017 | $99,000 | 0.0% | 57,432 | +43.0% | 0.00% | – |
Q1 2017 | $99,000 | -36.1% | 40,176 | -33.5% | 0.00% | – |
Q3 2016 | $155,000 | +198.1% | 60,455 | +77.7% | 0.00% | – |
Q2 2016 | $52,000 | -31.6% | 34,030 | -11.7% | 0.00% | – |
Q1 2016 | $76,000 | -14.6% | 38,521 | +33.7% | 0.00% | – |
Q4 2015 | $89,000 | -92.4% | 28,801 | -91.8% | 0.00% | – |
Q3 2015 | $1,177,000 | +89.5% | 351,297 | +110.0% | 0.00% | – |
Q2 2015 | $621,000 | +71.5% | 167,293 | +71.4% | 0.00% | – |
Q1 2015 | $362,000 | +1473.9% | 97,582 | +872.1% | 0.00% | – |
Q3 2014 | $23,000 | -97.9% | 10,038 | -97.3% | 0.00% | – |
Q2 2014 | $1,082,000 | -55.5% | 373,365 | -37.4% | 0.00% | -100.0% |
Q1 2014 | $2,434,000 | +6305.3% | 596,763 | +2603.7% | 0.00% | – |
Q1 2012 | $38,000 | – | 22,072 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Broadfin Capital, LLC | 2,030,604 | $4,285,000 | 0.70% |
Virtus ETF Advisers LLC | 180,348 | $381,000 | 0.48% |
Bain Capital Public Equity Management, LLC | 4,564,744 | $9,632,000 | 0.35% |
Baker Brothers Advisors | 18,315,802 | $38,646,000 | 0.34% |
Stanley-Laman Group, Ltd. | 483,773 | $1,021,000 | 0.22% |
FIRST MIDWEST BANK TRUST DIVISION | 493,689 | $1,042,000 | 0.13% |
GMT CAPITAL CORP | 3,875,546 | $8,178,000 | 0.08% |
Vident Investment Advisory, LLC | 640,270 | $1,351,000 | 0.06% |
SABBY MANAGEMENT, LLC | 307,987 | $650,000 | 0.06% |
Palo Alto Investors LP | 616,355 | $1,301,000 | 0.06% |